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Abstract 
Kolaviron is a mixture of bioflavonoids found in the nut of the West African edible 
seed Garcinia kola, and it has been reported to exhibit a wide range of 
pharmacological activities. In this study, we investigated the effects of kolaviron in 
neuroinflammation. The effects of kolaviron on the expression of nitric 
oxide/inducible nitric oxide synthase (iNOS), prostaglandin E2 
(PGE2)/cyclooxygenase-2, cellular reactive oxygen species (ROS) and the 
pro-inflammatory cytokines were examined in lipopolysaccharide (LPS)-stimulated 
BV2 microglial cells. Molecular mechanisms of the effects of kolaviron on NF-B and 
Nrf2/ARE signalling pathways were analysed by immunoblotting, binding assay, and 
reporter assay. RNA interference was used to investigate the role of Nrf2 in the 
anti-inflammatory effect of kolaviron. Neuroprotective effect of kolaviron was 
assessed in a BV2 microglia/HT22 hippocampal neuron co-culture. Kolaviron 
inhibited the protein levels of NO/iNOS, PGE2/COX-2, cellular ROS and the pro-
inflammatory cytokines (TNFα and IL-6) in LPS-stimulated microglia. Further 
mechanistic studies showed that kolaviron inhibited neuroinflammation by inhibiting 
IB/NF-B signalling pathway in LPS-activated BV2 microglia. Kolaviron produced 
antioxidant effect in BV2 microglia by increasing HO-1 via the Nrf2/ antioxidant 
response element (ARE) pathway. RNAi experiments revealed that Nrf2 is need for 
the anti-inflammatory effect of kolaviron. Kolaviron protected HT22 neurons from 
neuroinflammation-induced toxicity. Kolaviron inhibits neuroinflammation through 
Nrf2-dependent mechanisms. This compound may therefore be beneficial in 
neuroinflammation-related neurodegenerative disorders. 
Keywords: Kolaviron, Microglia, Neuroinflammation, Nrf2 signalling pathway, 
Neuroprotective 
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1. Introduction 
Accumulating evidence continues to link chronic neurodegenerative diseases such 
as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), 
amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) with chronic 
neuroinflammation. 
Chronic neuroinflammation is a self-perpetuating response that persists long after an 
initial injury or insult. It is characterised by prolonged activation of CNS-resident 
macrophages, the microglia and subsequent sustained release of pro-inflammatory 
mediators [1]. Microglial activation perpetuates the inflammatory cycle by activating 
other microglia, resulting in a further release of inflammatory factors [1]. 
Inflammatory signalling pathways following microglial activation therefore represent a 
prime target for inhibiting neuroinflammation-induced neurodegeneration. 
Oxidative stress has been strongly linked to the aetiology of many 
neurodegenerative diseases. According to Li et al. [2], accumulation of reactive 
oxygen and nitrogen species generated by inflammatory cells that is one of the 
mechanisms through which chronic inflammation contributes to diseases. The 
Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) is a redox sensitive 
transcription factor and a critical regulator of endogenous inducible defence systems 
in the body [3, 4]. Under physiological conditions, Nrf2 is sequestered in the 
cytoplasm by the regulatory protein Kelch-like ECH-associated protein 1 (Keap1) [3, 
5]. However, in response to oxidative stress, Nrf2 translocates to the nucleus and 
binds to anti-oxidant response elements (ARE) in the DNA, to initiate transcription of 
cytoprotective genes [4]. 
New information suggest that activation of Nrf2 is an important strategy in blocking 
neuroinflammation in the microglia. Recent findings indicate that restoration of redox 
balance through activation of Nrf2 may be a determining factor in restoring the 
microglia back to its resting inactivated state, and presents as a strategy for 
modulating neuroinflammation in neurodegenerative disorders [6]. A study by Koh et 
al. [3] showed that Nrf2 inhibits microglial hyperactivation by suppressing p38 MAPK 
and NF-B signalling pathway. Further evidence indicates that the hippocampi of 
Nrf2 knockout mice were shown to be hypersensitive to the neuroinflammation 
induced by LPS, as demonstrated by an increase in the inflammation markers iNOS, 
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IL-6, and TNFα, compared with the hippocampi of wild-type littermates [7]. Taken 
together, it has become clear that measures to activate Nrf2 in the microglia would 
be a significant strategy in reducing neuroinflammation. 
Kolaviron (Figure 1) is a mixture of bioflavonoids found in the nut of the West African 
edible seed, Garcinia kola. Kolaviron has been widely reported to produce a wide 
range of pharmacological activities. However, this flavonoid is mostly known for its 
antioxidant and anti-inflammatory activities. Kolaviron has been reported to prevent 
hepatotoxicity through inhibition of lipid peroxidation [8-10]. It has also been shown 
to be neuroprotective, an action that has been attributed to its antioxidant property 
[11-13]. In vivo and in vitro research have shown that kolaviron exhibited 
anti-inflammatory effects. In a study reported by Olaleye et al. [14], kolaviron 
inhibited carrageenan-induced rat paw oedema and suppressed TNFα, NO and 
PGE2 production in RAW 264.7 macrophages. These results were confirmed by a 
study reported by Abarikwu [15], who showed that the suppressive effects of 
kolaviron on the production of pro-inflammatory mediators in macrophages is 
possibly due to inhibition of both NF-B, Akt and MAPK signalling pathways. 
Farombi et al. [16] also showed that kolaviron prevented liver injury through inhibition 
of COX-2 and iNOS protein expressions, possibly by targeting NF-B and AP-1 
transcription factors. 
In this study, we have investigated the effect of kolaviron on neuroinflammation in 
LPS-activated BV2 microglia. We have also shown that kolaviron exhibits antioxidant 
effect in BV2 microglia through activation of HO-1/Nrf2/ARE cytoprotective 
mechanisms. 
2. Materials and methods 
2.1 Extraction of kolaviron 
Kolaviron was extracted from the seeds of Garcinia kola as earlier described [17]. 
The seeds were sliced, air-dried and powdered. The powdered seeds were defatted 
with n-hexane for 24 h. The defatted dried marc was then extracted with methanol. 
Kolaviron was fractionated from concentrated methanol extract using chloroform to 
give a golden yellow solid which consists of biflavanones-GB1, GB2 and 
kolaflavanone [Error! Reference source not found.] (Iwu et al, 1990). This was 
purified in a silica gel column with the elution of methanol and then, ethyl acetate, 
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and the final compound has a glittering golden-brown appearance. Kolaviron was 
dissolved in DMSO for experiments. 
2.2 Cell culture 
BV2 mouse microglia cell line ICLC ATL03001 (Interlab Cell Line Collection, Banca 
Bilogica e Cell Factory, Italy) were maintained in RPMI 1640 medium with 10 % 
foetal bovine serum (FBS) (Sigma), 2 mM l-glutamine (Sigma), 100 U/ml penicillin 
and 100 mg/ml streptomycin (Sigma) in a 5 % CO2 incubator at 37°C.  
HT22 mouse hippocampal neuronal cells were a kind gift from Dr Jeff Davies, and 
cultured in DMEM supplemented with 10 % FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin in a 5 % CO2 incubator at 37°C. 
2.3 Cell viability 
The colorimetric 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide 
(MTT) assay was performed to determine the viability of BV2 microglia incubated 
with or without LPS (100 ng/ml) in the presence of kolaviron (5-20 μM) for 24 h. 
Following LPS stimulation, culture media was replaced with media containing 
5 mg/ml MTT solution and incubated for 4 h. Thereafter, 200 μl of medium was 
removed from each well without disturbing the cell clusters, and 150μl of DMSO 
solution added to wells to dissolve the formazan crystals. Thorough mixing of the 
preparation was facilitated by shaking the plate for a few seconds before absorbance 
was read at 540 nm with a plate reader (Infinite F50, Tecan) [19]. 
2.4 Determination of TNFα and IL-6 production in LPS-activated BV2 microglia 
BV2 cells were stimulated with LPS (100 ng/ml) in the presence or absence of 
kolaviron (5-20 µM) for 24 h. Thereafter, culture supernatants were collected and 
centrifuged. Concentrations of TNFα and IL-6 in cell supernatants were analysed 
with a commercially available ELISA kit (BioLegend, UK), followed by measurements 
in a plate reader at a wavelength of 450 nm. 
2.5 Determination of PGE2 production in LPS-activated BV2 microglia 
Following pre-treatment with kolaviron (5-20 M) and stimulation with LPS 
(100 ng/ml) for 24 h, levels of PGE2 in BV2 cell culture medium were measured 
using commercially available enzyme immunoassay kit (Arbor Assays, Ann Arbor, 
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Michigan, USA) according to manufacturer’s instructions. Absorbance was read at 
450 nm in a microplate reader (Infinite F50, Tecan). 
2.6 Determination of NO production in LPS-activated BV2 microglia 
Following pre-treatment with kolaviron (5-20 M) and stimulation with LPS 
(100 ng/ml) for 24 h levels of nitrite in culture media were measured using 
commercially available Griess assay kit (Promega) according to the manufacturer’s 
instructions. Absorbance was measured at 540 nm in a microplate reader (Infinite 
F50, Tecan). 
2.7 Determination of cellular reactive oxygen species (ROS) 
The effect of LPS on intracellular ROS levels in BV2 cells was performed using the 
fluorescent 2’, 7’-dichlorofluorescin diacetate (DCFDA)-cellular reactive oxygen 
species detection assay kit (Abcam). BV2 microglia were incubated with 10 µM 
DCFDA for 30 min at 37C. After removal of excess DCFDA, cells were washed and 
then pre-treated with kolaviron (5-20 µM) for 30 min followed by stimulation with 
100 ng/ml LPS for 4 h at 37C. Intracellular production of ROS was measured by the 
fluorescence detection of dichlorofluorescein (DCF) as the oxidised product of DCFH 
on a microplate reader with an excitation wavelength of 485 nm and emission 
wavelength of 535 nm. 
2.8 Immunoblotting 
Following pre-treatment with kolaviron (5-20 M) and stimulation with LPS 
(100 ng/ml), cell lysates were prepared by washing cells with PBS, followed by 
addition of lysis buffer and phenylmethylsulfonyl fluoride (PMSF), and centrifugation 
for 10 min. Nuclear extracts were prepared using EpiSeeker Nuclear Extraction Kit 
(Abcam), according to the manufacturer's instructions. Briefly, cells were washed 
with cold PBS, followed by addition of 20 μl of pre-extraction buffer and incubation on 
ice for 10 min. Thereafter, cells were centrifuged at 12,000 rpm for 1 min. 
Supernatants were discarded, and 10 μl of extraction buffer was added to the pellet 
and incubated on ice for 15 min, followed by centrifugation at 13,500 rpm for 15 min 
at 4 °C. The resulting nuclear extracts in the supernatants were collected. 
Twenty-five micrograms of protein was subjected to sodium dodecyl 
sulfate-polyacrylamide (SDS) gel electrophoresis. Proteins were then transferred to 
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polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA) for 2 h. 
Membranes were then blocked at room temperature for 1 h and then incubated with 
primary antibodies overnight at 4°C. Primary antibodies used in the experiments 
were rabbit anti-iNOS (Santa Cruz, 1:500), rabbit anti-COX-2 (Santa Cruz, 1:500), 
rabbit anti-phospho-IBα (Santa Cruz, 1:250), rabbit anti-total IBα, rabbit anti-HO-1 
(Santa Cruz, 1:500) and rabbit anti-Nrf2 (Santa Cruz, 1:500). Blots were detected 
with Alexa Fluor® 680 goat anti-rabbit IgG (Life technologies, UK) using Licor 
Odyssey. Equal protein loading was assessed using rabbit anti-actin antibody 
(Sigma, 1:1000). 
2.9 NF-Bp65 ELISA 
Cultured BV2 cells were stimulated with LPS (100 ng/ml) for 1 h following treatment 
with kolaviron (5-20 µM). Thereafter, nuclear extracts were collected and analysed 
for levels of phospho-NF-Bp65 using ELISA (eBioscience), according to the 
manufacturer’s instructions. Absorbance was read at 450 nm. 
2.10 Reporter gene assays 
BV2 microglia were cultured as described above. At confluence, the cells were sub-
cultured (at a ratio of 1:3) 24 h before transfection. Thereafter, cells were harvested 
and re-suspended at 4 x 105 cells/ml in Opti-MEM containing 5% FBS and 1 % 
NEAA. Cells were seeded out in a solid white 96-well plates and incubated with 
pGL4.32[luc2P/NF-B-RE/Hygro] vector (Promega, UK), using Fugene 6 (Promega) 
transfection reagent (diluted 1:3 in serum-free Opti-MEM) and incubated for a further 
16 h at 37°C in 5% CO2 incubator. Following transfection, media was changed to 
OPTI-MEM and incubated for another 8 h. Thereafter, transfected cells were treated 
kolaviron (5-20 µM) and incubated for 30 min at 37°C followed by LPS (100 ng/ml) 
for 6 h. At the end of the stimulation, NF-B-mediated gene expression was 
measured by using One-Glo luciferase Assay kit (Promega), according to the 
manufacturer’s instructions. 
To carry out the ARE-dependent reporter gene assay, BV2 microglia were seeded 
out and incubated in solid white 96-well at 37°C for 24 h. A transfection cocktail was 
made by diluting ARE vector (pGL4.37 [luc2P/ARE/Hygro]; Promega) at a 
concentration of 1 ng DNA/µl in Fugene 6 transfection reagent diluted in OPTI-MEM. 
The cocktail was incubated at room temperature for 20 min, followed by addition of 
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8 µl to each well, followed by incubation for 18 h at 37°C. Thereafter, culture medium 
was changed to OPTI-MEM and incubated for 6 h at 37°C. Cells were then treated 
with kolaviron (5-20 µM) and incubated at 37°C for 18 h. Following incubation, plates 
were allowed to cool at room temperature for 15 min. Thereafter, 80 µl of luciferase 
buffer containing luminescence substrate was added to each well and luminescence 
read with FLUOstar OPTIM reader (BMG LABTECH). 
2.11 DNA binding assays 
An ELISA-based DNA binding assay was used to investigate the effects of kolaviron 
on DNA binding of NF-B. BV2 microglia were treated with 5, 10 and 20 M 
kolaviron 30 min before stimulation with LPS (100 ng/ml). One hour later, nuclear 
extracts were prepared using EpiSeeker Nuclear Extraction Kit (Abcam), according 
to the manufacturer's instructions. DNA binding assay was carried on nuclear 
extracts using the TransAM NF-B transcription factor ELISA kit (Activ Motif, 
Belgium) according the manufacturer’s instructions. The ELISA kit employs a 96-well 
plate to which an oligonucleotide containing the NF-B consensus site 
(5’-GGGACTTTCC-3’) has been immobilised. Briefly, 30 l of complete binding 
buffer were added to each well, followed by 20 g nuclear extract samples. The plate 
was covered and rocked (100 rpm) for 1 h at room temperature. This was followed 
by addition of NF-B antibody (1:1000; 1 h) and HRP-conjugated antibody (1:1000; 
1 h). Absorbance was read on a Tecan F50 microplate reader at 450 nm. 
To investigate DNA binding of Nrf2, BV2 microglia were treated with kolaviron 
(5-20 M). Nuclear extracts were added to 96-well plates on which has been 
immobilised oligonucleotide containing the ARE consensus binding site 
(5’-GTCACAGTGACTCAGCAGAATCTG-3’). Assay procedure was as described for 
NF-B, using an Nrf2 antibody (1:1000; 1 h).  
2.12 Nrf2 Gene silencing experiments 
Small interfering RNA (siRNA) targeted at Nrf2 (Santa Cruz Biotechnology) was 
used to knockout Nrf2. BV2 cells were cultured and incubated at 37°C in a 5% CO2 
incubator until 70-80 % confluent. Thereafter, 2 µl Nrf2 siRNA duplex were diluted 
into 100 µl of siRNA transfection medium (Santa Cruz Biotechnology). In a separate 
tube, 2 µl of transfection reagent (Santa Cruz biotechnology) was diluted into 100 µl 
of siRNA transfection medium. The dilutions were mixed gently and incubated for 
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30 min at room temperature. Next, cells were incubated in Nrf2 siRNA transfection 
cocktail for 6 h at 37°C. Following transfection, media was changed in all cells to 
complete media and incubated for a further 18 h. Effects of kolaviron (20 M) on NO, 
PGE2, TNFα and IL-6 production in LPS-stimulated normal and Nrf2-silenced BV2 
cells were then investigated. Nuclear NF-Bp65 ELISA and NF-B DNA binding 
assays were conducted in LPS-stimulated normal and Nrf2-silenced BV2 microglia 
treated with kolaviron (20 M). 
2.13 BV2 microglia/HT22 hippocampal neuron co-culture 
Neuroprotective effects of kolaviron was investigated using a transwell co-culture 
system. BV2 cells were cultured at the density of 5 x 104 cells/ml on the transwell 
insert (pore size 0.4 µm; Corning) in 96-well plate placed above the HT22 neuronal 
layer. Twenty-four hours after establishing co-culture, BV2 cells were pre-treated 
with kolaviron (5-20 µM) and then stimulated with LPS (1 µg/ml) for 24 h. At the end 
of the experiment, 200 µl MTT solution (5 mg/ml) was added to each well containing 
HT22 neurons and incubated at 37°C for 4 h. Then, 200 μl of medium was removed 
and 150 μl of DMSO solution added to wells to dissolve the formazan crystals. 
Thorough mixing of the preparation was facilitated by shaking the plate for a few 
seconds before absorbance was read at 540 nm with a plate reader. 
Supernatants were also collected from the BV2 microglia layer and analysed for 
levels of TNFα, IL-6, NO and PGE2. 
2.14 Cellular DNA fragmentation assay in HT22 hippocampal neurons 
co-cultured with BV2 microglia 
The effect of microglial activation on cellular DNA fragmentation in HT22 cells was 
conducted using an assay kit (Roche Diagnostics, Mannheim, Germany), according 
to the manufacturer’s instructions. HT22 neurons were co-cultured with BV2 cells 
grown in transwells. Then, HT22 layers were labelled with 5-bromo-2’-deoxyuridine 
(BrdU) for 12 h. Following labelling; BV2 layer was treated with kolaviron (5-20 µM) 
30 min prior to LPS (1 µg/ml) stimulation for 24 h. Thereafter, HT22 cells were 
collected, centrifuged at 250 g for 10 min and supernatants removed. The cells were 
then lysed with 200 µl of buffer and incubated for 3 min at room temperature. Cells 
were centrifuged again 250 g for 10 min and supernatants removed. The labelled 
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DNA in the supernatants as a result of DNA fragmentation was measured using 
ELISA with an anti-BrdU antibody. 
2.15 Statistical analysis 
All experiments were performed at least three times and in triplicates unless 
otherwise stated. Data in figures and text were expressed as mean ±SEM. Statistical 
analysis was performed using one way ANOVA with post-hoc Student Newman-
Keuls test (multiple comparisons). 
3. Results 
3.1 Kolaviron did not affect the viability of BV2 microglia 
Cell viability experiments were carried out to determine whether concentrations of 
kolaviron used in this study affected viability of BV2 microglia. Figure 2 shows that 
kolaviron at concentrations ranging from 5 to 20 µM did not produce cytotoxicity in 
BV2 microglia after 24 h. 
3.2 Kolaviron prevented the production of TNFα and IL-6 in LPS-activated BV2 
microglia 
To investigate the effect of kolaviron on the secretion of pro-inflammatory cytokines, 
BV2 cells were treated with LPS in the presence or absence of kolaviron for 24 h. 
Thereafter, levels of TNFα and IL-6 were measured. Expectedly, stimulation with 
LPS induced a marked increase in the levels of TNFα and IL-6. We observed that 
kolaviron dose-dependently reduced the secretion of TNFα and IL-6 (Figure 3A and 
B). 
3.3 Kolaviron produced iNOS-mediated reduction of NO secretion in LPS-
activated BV2 microglia 
Microglial activation during neuroinflammation results in increased production of 
nitric oxide, which reacts with oxygen to produce the highly reactive peroxinitrite 
(ONOO•) anion. As expected, there was an increase in the levels of nitrite (a marker 
of NO production) following stimulation of BV2 microglia with LPS (100 ng/ml). LPS 
stimulation of BV2 microglia caused an increase in NO production. Pre-treatment 
with kolaviron (5-20 µM) resulted in a significant and concentration-dependent 
reduction in nitrite production (Figure 4A). Encouraged by this observation, we used 
western blot to evaluate the effects of kolaviron on protein levels of iNOS in LPS-
11 
 
activated microglia and showed that the compound significantly reduced iNOS 
protein at 5 µM (~1.3-fold, p<0.001), 10 µM (~2-fold, p<0.001) and 20 µM (~3.3-fold, 
p<0.001) (Figure 4B). 
3.4 Kolaviron produced COX-2-mediated reduction of PGE2 secretion in LPS-
activated BV2 microglia 
Studies have shown that PGE2 is a common mediator in brain inflammation [20]. It 
has also been shown that PGE2 is released following stimulation of microglia with 
LPS [21]. Hence we investigated whether kolaviron could suppress PGE2 production 
in LPS-activated BV2 microglia. Expectedly, LPS stimulation of BV2 microglia 
produced elevated levels of PGE2 in cell supernatants (Figure 5A), an outcome that 
was reduced by 5 µM (~1.4-fold, p<0.01), 10 µM (~2-fold, p<0.001) and 10 µM (~2.2-
fold, p<0.001) kolaviron. As shown in Figure 5B, kolaviron also produced 1.3-2.0-fold 
reduction in elevated levels of COX-2 protein in LPS-activated BV2 microglia. 
3.5 Cellular ROS production was suppressed by kolaviron 
Microglia-mediated inflammation is known to induce oxidative damage [22, 23]. To 
test the effects of kolaviron on cellular ROS generation, the intracellular ROS was 
determined by the DCFDA fluorescence detection. Stimulating BV2 cells with LPS 
(100 ng/ml) induced a characteristic increase in cellular ROS generation (Figure 6). 
This increase was significantly (p<0.001) inhibited by kolaviron (5-20 µM). 
3.6 Kolaviron inhibited neuroinflammation by targeting IB/NF-B signalling 
pathway 
The genes encoding inflammatory proteins produced in response to microglial 
activation, such as the pro-inflammatory cytokines, PGE2/COX-2, NO/iNOS and the 
ROS is under the transcriptional control of NF-B. Consequently, we explored the 
NF-B signalling pathway as a possible mechanistic target for the inhibitory action of 
kolaviron in neuroinflammation. 
In unstimulated microglia NF-B exists complexed to the inhibitory IB. Upon 
microglial activation by LPS, IB is phosphorylated and undergoes proteasomal 
degradation. This results in nuclear translocation of NF-Bp65 sub-unit and 
subsequent transcriptional activity. 
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Our first line of investigation in this respect therefore focused on IB phosphorylation 
and degradation. We showed that LPS induced a characteristic increase in 
phospho-IB following stimulation with LPS (Figure 7A). Following pre-treatment with 
kolaviron, levels of phospho-IB protein was significantly (p<0.001) reduced in a 
concentration-dependent fashion (5 µM, ~1.4-fold; 10 µM, ~1.7-fold; 20 µM, ~2-fold). 
Similarly, LPS treatment of BV2 microglia induced degradation of IB (Figure 7B), a 
phenomenon that was significantly and dose-dependently attenuated by 
pre-treatment with kolaviron. Figure 7C shows the effect of kolaviron on nuclear 
translocation of NF-Bp65 sub-unit following stimulation with LPS. Evaluation of 
nuclear phospho-NF-Bp65 using ELISA revealed that prior incubation with kolaviron 
significantly (p<0.001) prevented translocation of NF-Bp65 to the nucleus (5 µM, 
~1.4-fold; 10 µM, ~2.1-fold; 20 µM, ~2.2-fold). These results suggest that kolaviron 
modulates NF-B signalling by interfering with the IB/NF-B complex. 
Encouraged by these results, we decided to assess the effect of kolaviron on binding 
of NF-Bp65 to an immobilised 5’-GGGACTTTCC-3’ oligonucleotide, which confers 
the NF-B binding site. This ELISA method provides specific and quantitative data 
on DNA binding of nuclear NF-B. Using the method, we could demonstrate that 
LPS induced a marked DNA binding of NF-B in BV2 microglia (Figure 7D). We 
however observed that nuclear extracts from kolaviron treated cells showed 
significantly reduced (p<0.001) DNA binding by NF-B. There was a ~4- and ~5-fold 
inhibition of DNA binding by 10 µM and 20 µM concentrations of kolaviron, 
respectively. 
Finally, we measured NF-B activity directly using reporter genes controlled by an 
NF-B response element. Due to the rapid activation and inactivation of NF-B 
following activation, the luciferase reporter assay was used in our experiments. BV2 
microglia were transfected with the pGL4.32 [luc2P/NF-B-RE/Hygro] vector and 
then stimulated with LPS (100 ng/ml). Our results showed that kolaviron produced a 
concentration-dependent and significant (p<0.001) inhibition of luciferase activity, 
demonstrating inhibition of NF-B activity directly (Figure 7E). 
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3.7 Kolaviron activated HO-1/Nrf2/ARE antioxidant protective mechanism in 
BV2 microglia 
The expression of the antioxidant protein HO-1 has been shown to mediate the 
resolution of neuroinflammation [24]. We were therefore in evaluating whether 
activation of HO-1 might be contributing to the anti-neuroinflammatory effects of 
kolaviron. Using western blot, we showed that treatment of BV2 microglia with 
kolaviron resulted in significant increase in the protein expression of HO-1 
(Figure 8A).  
HO-1 expression is controlled by Nrf2, which binds to a specific DNA sequence 
(ARE) present in the promoter region of phase II enzymes such as HO-1, and 
enhances their transcription. Based on our observation that kolaviron increases the 
protein expression of HO-1, we further determined whether this effect was mediated 
by Nrf2. Western blot analysis showed that kolaviron increased levels of Nrf2 in the 
nucleus, when compared with untreated (control) cells (Figure 8B). Treatment with 5, 
10 and 20 µM kolaviron were shown to induce ~2.5-, ~3- and ~4-fold increase in 
nuclear Nrf2.  
We decided to explore the effect of kolaviron further by using a luciferase reporter 
which is under the control of a promoter containing the ARE consensus. Using this 
reporter assay, we observed that kolaviron produced a dose-dependent increase in 
ARE luciferase activity (Figure 8C). This seems to suggest that kolaviron increases 
the transcriptional activity of Nrf2, which might explains its effect on HO-1. We 
confirmed these observations with an Nrf2 binding assay, which employs 
immobilised oligonucleotide containing the ARE binding site 
5’-GTCACAGTGACTCAGCAGAATCTG-3’. This experiment revealed that kolaviron 
(5-20 µM) produced significant and dose-dependent activation, and hence DNA 
binding of Nrf2 (Figure 8D).  
3.8 Inhibition of neuroinflammation by kolaviron is dependent on Nrf2 
Based on our results showing that kolaviron inhibits neuroinflammation and activates 
the HO-1/Nrf2 antioxidant mechanisms, we hypothesised that activation of Nrf2 
contributed to the inhibitory effect of the flavonoid on neuroinflammation. 
Consequently, Nrf2 siRNA duplex was transfected into BV2 microglia, followed by 
stimulation with LPS in the presence or absence of kolaviron (20 µM). After 24 hours, 
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supernatants were collected and analysed for levels of secreted TNFα, IL-6, NO and 
PGE2. 
Expectedly, production of NO, PGE2, TNFα and IL-6 in Nrf2-silenced BV2 microglia 
was significantly (p<0.05) increased, in comparison with control cells (Figures 9A-D). 
In control cells, pre-treatment with kolaviron (20 µM) resulted in significant (p<0.05) 
reduction in pro-inflammatory mediators. However, silencing Nrf2 resulted in almost 
complete reversal of the anti-inflammatory effect of kolaviron, with significant 
increases in the production of NO, PGE2, TNFα and IL-6, when compared to control 
cells (Figures 9A-D). 
In order to confirm the role of Nrf2 in the anti-inflammatory effect of kolaviron, we 
compared its actions on protein levels of nuclear phospho-NF-Bp65 following LPS 
stimulation in control and Nrf2-silenced BV2 cells. We observed that protein 
expression of phospho-NF-Bp65 in nuclear extracts of Nrf2-silenced BV2 microglia 
was significantly increased, in comparison with control cells (Figure 9E). 
Interestingly, reduction in LPS-induced increase in nuclear phospho-NF-Bp65 by 
kolaviron (20 µM) was completely reversed following transfection of BV2 microglia 
with Nrf2 siRNA (Figure 9E). Similar results were obtained in experiments to 
investigate the effects of kolaviron (20 µM) on DNA binding of NF-B. Following Nrf2 
knockout, we observed that inhibition of LPS-induced DNA binding by kolaviron 
(20 µM) was completely reversed (Figure 9F). Our results suggest a loss in the anti-
inflammatory activity of kolaviron in BV2 microglia in the absence of the Nrf2 gene. 
In order to confirm that Nrf2 gene was efficiently silenced in these experiments, 
nuclear extracts were prepared from both control and Nrf2-silenced BV2 cells. 
Western blot for Nrf2 showed basal levels of Nrf2 protein in control cells. In cells 
transfected with Nrf2 siRNA, levels of Nrf2 protein were significantly reduced, 
suggesting that the gene encoding this protein was effectively silenced (Figure 9G). 
3.9 Kolaviron protected HT22 hippocampal neurons from 
neuroinflammation-induced neuronal death 
During neuroinflammation, microglial activation by LPS results in significant release 
of pro-inflammatory mediators such as the ROS, NO, PGE2, TNFα and IL-6 which 
are toxic to adjacent neurons.  
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To investigate the neuroprotective effect of kolaviron in microglia-mediated 
neurotoxicity, we established a BV2 microglia/HT22 neuron transwell co-culture. The 
microglia layer was then stimulated with LPS (1 µg/ml) in the presence or absence of 
kolaviron (5-20 µM), as usual. After 24 h, viability of HT22 hippocampal neurons was 
determined using the MTT assay. Figure 10A shows that LPS stimulation of BV2 
microglia layer resulted in significant reduction in neuronal viability, when compared 
with unstimulated control. However, monolayers of HT22 neurons co-cultured with 
kolaviron pre-treated BV2 microglia showed significant (p<0.05) increased viability, 
thus demonstrating neuroprotection. 
To confirm the roles of released pro-inflammatory mediators in 
neurotoxicity/neuroprotection, supernatants were taken from the microglia layer and 
analysed for NO, PGE2, TNFα and IL-6. Results showed elevated levels of NO, 
PGE2, TNFα and IL-6 in the supernatants of LPS-stimulated microglia 
(Figures 10B-E). Expectedly, pre-treatment with kolaviron (5-20 µM) resulted in 
dose-dependent and significant (p<0.05) reduction in NO, PGE2, TNFα. Reduction in 
IL-6 was achieved with 10 and 20 µM kolaviron. 
Following apoptotic death of neurons, DNA fragments are released from the 
cytoplasm of apoptotic cells after lysis with a non-ionic detergent. A colorimetric DNA 
fragmentation assay was conducted on the HT22 neurons. There was ~1.5-fold 
increase in DNA fragmentation of HT22 neurons co-cultured with LPS-stimulated 
BV2 microglia, when compared with neurons co-cultured with unstimulated BV2 cells 
(Figure 11). However, neuronal DNA fragmentation was significantly reduced when 
BV2 cells were pre-treated with kolaviron prior to LPS (5 µM, ~1.2-fold; 10 µM, ~1-
fold; 20 µM, ~0.7-fold, compared with unstimulated cells). 
4. Discussion 
The release of neurotoxic pro-inflammatory mediators from microglia, in response to 
activators such as LPS results in the death of adjacent neurons. For example, 
excessive NO synthesis under neuroinflammation is now widely accepted to result in 
the formation of reactive nitrogen species and neuronal cell death [25]. Similarly, 
PGE2 has been shown to induce neuronal death through activation of EP2 receptors 
[26]. Pro-inflammatory cytokines such as TNFα and IL-6, as well as ROS have been 
implicated in neuronal death which characterise neurodegenerative diseases [27]. In 
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this study we showed that kolaviron inhibited the production of pro-inflammatory 
cytokines (TNFα and IL-6), NO, PGE2 and cellular ROS in BV2 microglia stimulated 
with LPS. We further showed that the effect of kolaviron on NO and PGE2 
production, were mediated through inhibition of iNOS and COX-2 proteins, 
respectively. To our knowledge, this is the first study showing inhibition of 
neuroinflammation by kolaviron in BV2 microglia. 
Similar studies in peripheral cells have shown anti-inflammatory activity by kolaviron. 
Using RAW 264.7 murine macrophages, studies have shown that kolaviron inhibited 
PGE2, NO and TNFα release following LPS stimulation [14]. Interestingly, another 
study by Abarikwu [15] reported that kolaviron inhibited LPS induced secretion of 
IL-6 but not TNFα in RAW 264.7 macrophages. Kolaviron was also shown to 
suppress the expressions of TNFα, and IL-6, and IL-1α genes in LPS-stimulated 
93RS2 sertoli cells [28]. 
During neuroinflammation, NF-B activation controls the expression of 
pro-inflammatory cytokines, iNOS/NO, PGE2/COX-2 and the ROS to trigger a 
self-perpetuating process resulting in progressive neuronal damage. We therefore 
aimed to identify the role of this critical transcription factor in the 
anti-neuroinflammatory activity of kolaviron. Firstly, we determined the effect of 
kolaviron on phosphorylation and degradation of IB protein, a process that is critical 
to NF-B activation. We showed that kolaviron produced dual inhibition of 
phosphorylation and degradation of NF-B, as well as nuclear translocation of the 
p65 subunit, suggesting that this biflavonoid acts to stabilise NF-B in the microglial 
cytoplasm following activation by LPS.  
In order to determine whether kolaviron acts by interfering with the transcriptional 
activity of NF-B, or by inhibiting NF-B activation upstream of its nuclear activity, we 
analysed the DNA binding activity of NF-B in LPS-activated BV2 microglia and 
evaluated the modulatory effect of kolaviron on this process. Our experiments 
revealed that kolaviron inhibited the activation and binding of NF-Bp65 subunit to its 
target DNA. We also employed a luciferase reporter gene under the control of a 
promoter containing the NF-B consensus sequence, to demonstrate the inhibitory 
effect of kolaviron on NF-B activation in LPS-stimulated BV2 microglia. These 
results provide confirmatory evidence to show that kolaviron blocks nuclear 
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activation of NF-B, as well as the upstream events which occur prior to nuclear 
activation. 
In RAW264.7 macrophages, higher concentrations of kolaviron (50 and 100 µM) 
than those used in this study produced a similar effect on LPS-induced 
phosphorylation and degradation of IB [15]. It therefore appears that BV2 microglia 
are more sensitive to the actions of this biflavonoid than peripheral macrophages 
such as the RAW264.7 cells. Studies in rats have reported that kolaviron blocked 
DNA binding activity of NF-B induced by dimethyl nitrosamine [16]. LPS is known to 
trigger NF-B activation through TLR4 signalling. However, studies have shown that 
dimethyl nitrosamine could be activating the PI3K-Akt/PKB pathway inimmune cells, 
which then contributes to the activation of NF-B [29]. 
Several studies have employed various models to demonstrate the antioxidant 
property of kolaviron and suggested that this property might be responsible for its 
neuroprotective effects [11-13]. In view of the role of played by the activation of the 
Nrf2/ARE antioxidant protective mechanism in restoring the microglia to its resting 
inactivated state, we investigated the effect of kolaviron on the activation of 
Nrf2/ARE in BV2 microglia. Firstly, we were able to show that the protein level of the 
phase II enzyme HO-1 was significantly increased by kolaviron. There have been 
several suggestions in the scientific literature, indicating that HO-1 expression helps 
in mediating the resolution of inflammation, including neuroinflammation [24, 30].  
As HO-1 expression is under the control of Nrf2, we further investigated the effects 
of kolaviron on the activation of this transcription factor. In the presence of kolaviron, 
there was an increase in nuclear accumulation of Nrf2 protein in BV2 microglia. This 
effect was accompanied by an increase in the transcriptional activity and DNA 
binding of Nrf2 in cells treated with kolaviron. These observations indicate that the 
antioxidant activity of kolaviron, through activation of Nrf2/HO-1 axis may be 
contributing to its anti-neuroinflammatory activity. To our knowledge, this is the first 
study demonstrating that kolaviron could activate the Nrf2/HO-1 system in the 
microglia. Similar effects have been shown for natural antioxidants such as tiliroside 
[31] and other Small molecule activators of the Nrf2-HO-1 [32]. 
Nrf2 mediates anti-neuroinflammatory activity through a direct inhibition of NF-B 
signalling pathway [3, 7]. We therefore thought that it might be interesting to 
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determine whether Nrf2 is a requirement for the anti-inflammatory effect of kolaviron 
in BV2 microglia. To achieve this we stimulated both control and Nrf2 siRNA 
transfected microglia with LPS in the presence and absence of kolaviron (20 µM). 
Levels of pro-inflammatory proteins were then measured in culture supernatants. 
Our results clearly indicate that silencing Nrf2 in BV2 microglia resulted in the 
reversal of suppressive effects on NO, PGE2, TNFα and IL-6 production in BV2 
microglia. Similarly, inhibition of nuclear accumulation of p65 subunit as well as DNA 
binding by kolaviron were reversed by silencing Nrf2 in the microglia. Taken 
together, it is suggested that Nrf2 activation is a critical requirement for the inhibition 
of neuroinflammation by kolaviron. This observation appears to explain, at least in 
part, the molecular mechanism of action of kolaviron in neuroinflammation. 
It is well established that microglial cells can be toxic to neurons through cell–cell 
contact-dependent mechanisms [33]. A transwell co-culture system was therefore 
used to study neuroprotection by kolaviron against microglia-induced toxicity. To 
achieve neurotoxicity, a high concentration (1 µg/ml) of LPS was used to activate 
microglia. Results showed that kolaviron protected neurons from death induced by 
microglial activation. In order to confirm the role of released mediators in 
neurotoxicity, supernatants from the microglial layer were analysed for levels of 
PGE2, NO, TNFα and IL-6. Interestingly, levels of released inflammatory mediators 
correlated with neuronal survival, suggesting that kolaviron prevented neuronal 
death by inhibiting neuroinflammation in the microglia. 
5. Conclusions 
The present study demonstrates that kolaviron inhibits neuroinflammation and 
activates the Nrf2/HO-1 protective mechanism. We also suggest that the inhibitory 
effect of this biflavonoid compound is dependent on Nrf2.  
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Figure Legends 
Figure 1. Structural representation of kolaviron 
Figure 2. Kolaviron (5-20 µM) did not affect the viability of BV2 microglia with or 
without LPS (100 ng/ml) for 24h. Results are expressed as means ± SEM of 
3 independent experiments. 
Figure 3. Kolaviron suppressed (A) TNFα and (B) IL-6 production in LPS-activated 
BV2 cell line. Cells were treated with or without kolaviron (5-20 µM) followed by LPS 
(100 ng/ml) treatment for 24 h. Production of TNFα and IL-6 was assessed in culture 
supernatants using an ELISA kit. Statistical analyses were carried out using one-way 
ANOVA with post hoc Student Newman–Keuls test (multiple comparisons). Results 
are expressed as means ± SEM of 3 independent experiments. (*p < 0.05, 
**p < 0.01, ***p < 0.001). 
Figure 4. Kolaviron inhibited LPS-induced iNOS-mediated NO production by in BV2 
microglia. Cells were pre-treated with indicated concentrations of kolaviron for 
30 min prior adding LPS (100 ng/ml) for 24h. NO accumulation in the supernatants 
was measured using Griess assay kit (A). Levels of iNOS protein was determined 
using western blotting (B). Statistical analyses were carried out using one-way 
ANOVA with post hoc Student Newman–Keuls test (multiple comparisons). Results 
are expressed as means ± SEM of 3 independent experiments. (*p < 0.05, 
**p < 0.01, ***p < 0.001). 
Figure 5. Kolaviron suppressed LPS-induced PGE2 production (A) by inhibiting 
COX-2 protein (B) in BV2 microglia. Cells were pre-treated with indicated 
concentrations of kolaviron for 30 min prior adding LPS (100 ng/ml) for 24h. 
Supernatants were subjected to EIA to evaluate PGE2 levels. Cell lysates were 
subjected to western blot to determine COX-2 expression. Statistical analyses were 
carried out using one-way ANOVA with post hoc Student Newman–Keuls test 
(multiple comparisons). Results are expressed as means ± SEM of 3 independent 
experiments. (*p < 0.05, **p < 0.01, ***p < 0.001).  
Figure 6. Kolaviron reduced LPS-induced cellular ROS generation in BV2 microglia. 
Cellular ROS levels were measured using DCFDA-cellular reactive oxygen species 
detection assay kit. Statistical analyses were carried out using one-way ANOVA with 
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post hoc Student Newman–Keuls test (multiple comparisons). Results are expressed 
as means ± SEM of 3 independent experiments. (*p < 0.05, **p < 0.01, ***p < 0.001). 
Figure 7. Kolaviron inhibits IB /NF-B signalling pathway in LPS-activated BV2 
microglia. Cells were pre-treated with kolaviron (5-20 µM) for 30 min and incubated 
prior to stimulation with LPS (100 ng/ml) for a further 30 min. Protein levels of 
phospho-(A) and total IB (B) were determined with western blot. Nuclear extracts 
were prepared from BV2 microglia pre-treated with indicated concentrations of 
kolaviron 30 min before stimulation with LPS for 60 min, and analysed for 
p-NF-Bp65 using an ELISA kit (C). DNA binding activity was evaluated with nuclear 
extracts in an ELISA-based DNA binding assay (D). (E) Effect of kolaviron on NF-B-
luc reporter gene activity. Cells transfected with the reporter plasmid 
(luc2P/NF-B-RE/Hygro) were treated with kolaviron (5, 10, and 20 μM) with or 
without LPS (100 ng/ml) for 6 h, and the reporter gene assay was performed. 
Statistical analyses were carried out using one-way ANOVA with post hoc Student 
Newman–Keuls test (multiple comparisons). Results are expressed as means ± 
SEM of 3 independent experiments. (*p < 0.05, **p < 0.01, ***p < 0.001). 
Figure 8. Kolaviron increased HO-1 via activation of Nrf2/ARE pathway in BV2 
microglia. (A) Western blot analysis shows the effects of kolaviron on HO-1 protein 
expression. Cell lysates were obtained from BV2 cells treated with kolaviron (5, 10 
and 20 μM) for 24 h. Quantification data are shown in the graph (n = 3). (B) Western 
blot for Nrf2. Nuclear extracts were prepared from BV2 cells treated with kolaviron 
(5, 10 and 20 μM) for 1 h. Quantification data are shown in the graph (n = 3). (C) 
Effect of kolaviron on ARE-luc reporter gene activity. Cells transfected with the 
reporter plasmid (ARE-luc) were treated with kolaviron (5, 10 and 20 μM) for 6 h, and 
reporter gene assay was performed. (D) EMSA for Nrf2. Nuclear extracts were 
prepared from BV2 cells treated with kolaviron for 1 h and incubated with the Nrf2 
oligonucleotide. Statistical analyses were carried out using one-way ANOVA with 
post hoc Student Newman–Keuls test (multiple comparisons). Results are expressed 
as means ± SEM of 3 independent experiments. (*p < 0.05, **p < 0.01, ***p < 0.001). 
Figure 9. Anti-inflammatory activity of Kolaviron is dependent on Nrf2. BV2 microglia 
were transfected with Nrf2 siRNA and treated with kolaviron (20 µM), followed by 
LPS (100 ng/ml) for 24 h. Supernatants were analysed for levels of NO (A), PGE2 
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(B), TNFα (C) and IL-6 (D). Nuclear extracts (LPS stimulation, 1 h) were also 
analysed for nuclear p-NF-Bp65 subunit using ELISA (E), and DNA binding (F). 
Western blot experiments on nuclear extracts showing efficiency of Nrf2 siRNA 
transfection (G). Statistical analysis was performed using one way ANOVA with post-
hoc Student Newman-Keuls test (multiple comparisons). (*p < 0.05, **p < 0.01, ***p 
< 0.001), (θθθp < 0.001), (&&&p < 0.001). 
Figure 10. Kolaviron produced neuroprotective effect in microglia-mediated HT22 
hippocampal neuron death. BV2 microglia were seeded in transwell inserts and the 
inserts were placed on top of the wells containing the HT22 neuronal culture. The 
microglia layer was treated with kolaviron (5-20 µM) for 30 min prior to stimulation 
with LPS (1 µg/ml) for 24 h. (A) Viability of HT22 hippocampal neuron was assessed 
using MTT assay. Supernatants were collected from the microglia monolayer and 
assessed for levels of TNFα, IL-6, NO and PGE2 (B-E). Statistical analyses were 
carried out using one-way ANOVA with post hoc Student Newman–Keuls test 
(multiple comparisons). Results are expressed as means ± SEM of 3 independent 
experiments. (*p < 0.05, **p < 0.01, ***p < 0.001). 
Figure 11. Kolaviron prevented DNA fragmentation of HT22 hippocampal neurons 
exposed to LPS (1 µg/ml)-activated BV2 microglia. BV2 microglia were seeded in 
transwell inserts and the inserts were placed on top of the wells containing the HT22 
neuronal culture. This was followed by labelling of neuronal layer with BrdU for 12 h. 
Thereafter, microglia layer was pre-incubated with kolaviron (5-20 µM) for 30 min 
followed by LPS (1 µg/ml) treatment for 24 h. Thereafter labelled DNA from lysates 
were collected and analysed using ELISA. Statistical analyses were carried out using 
one-way ANOVA with post hoc Student Newman–Keuls test (multiple comparisons). 
Results are expressed as means ± SEM of 3 independent experiments, (*p < 0.05, 
**p < 0.01, ***p < 0.001).
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